Naive T cell (null)

A naive T cell is a type of T lymphocyte (white blood cell subtype) that has completed development in the thymus and has passed both positive and negative selection, but has not yet encountered its specific antigen in peripheral tissues. Naive T cells include both CD4+ (helper) and CD8+ (cytotoxic) T cell subsets and are central to the adaptive immune response, capable of recognizing and responding to novel pathogens and initiating a specific immune response upon encounter with their cognate antigen. Phenotypically, they are identified by the high expression of L-selectin (CD62L), CCR7, CD45RA, and CD127 (IL-7Rα), with absence of activation or memory markers such as CD25, CD44, CD69, or CD45RO. Maintenance and diversity of the naive T cell pool are crucial for immune system responsiveness throughout life, and this pool decreases with age due to thymic involution but is maintained by homeostatic peripheral proliferation. Naive T cells are not a molecular drug target (such as a receptor or enzyme), but a cellular population fundamental to immunology and are a source for various T cell-based immunotherapies. Their dysfunction or loss is associated with immunodeficiency, poor vaccine response, and increased autoimmunity or cancer risk in aging populations. Explanation of "is_target" and "is_incorrect": Naive T cell refers to a developmental/maturational state of a T lymphocyte, not a discrete molecular entity, receptor, or classic drug target. Thus, it should not be categorized as a therapeutic target for molecular drugs. It is not wrong per se, but is considered "incorrect" in the context of listings of molecular targets (receptors, enzymes, etc.) for pharmacological modulation per your schema. If you require information on a molecular target specific to naive T cell function or phenotype (e.g., IL-7 receptor, CCR7), please specify.

Other names

Th0 cellnaive Th cellnaive CD4+ T cellnaive CD8+ T cell

Not applicable (see above)